Healthcare Newsdesk Magazine Talks About Noctura 400
Adoption of sight-saving sleep mask could save the NHS millions
PolyPhotonix’s Noctura 400 sleep mask has been adopted by Ashford and St Peter’s NHS Foundation Trust as a pioneering treatment to prevent blindness in patients suffering from diabetic retinopathy. The mask has shown improvement and stabilisation of diabetic eye disease in 96% of patients and is a non-invasive alternative to current, later-stage invasive treatments such as eye injections. The sleep mask could potentially save the health service millions of pounds a year and deliver cost savings estimated in excess of £180m per year if adopted across the NHS. The mask maintains or improves patient’s vision and the physiological effects of diabetes on their eyes by delivering a precise level of light at a particular wavelength during a patient’s normal hours of sleep in a home-based setting. The current NHS pathway involves monitoring patients with early signs of diabetic retinopathy until their eyes deteriorate and they qualify for treatment intervention. However, the Noctura 400 sleep mask uses intervention at an early stage to prevent future problems before they start. Phentermine